Business Combinations (Tables)

12 Months Ended

Dec. 31, 2025

The total consideration and the fair values determined in

accordance with IFRS 3 of the identified net assets acquired of Biotheus as of January 31, 2025, are as follows:



		Fair value recognized on acquisition
(in millions €)		Biotheus

Assets
Intangible assets		172.8
Property, plant and equipment		70.7
Cash and cash equivalents		122.4
Other assets non-current and current		20.6
Total assets		386.5

Liabilities
Non-current liabilities		36.3
Current liabilities		55.1
Total liabilities		91.4

Total identifiable net assets at fair value		295.1

Bargain from the acquisition		(15.0)
Total consideration		280.1

Consideration
Total purchase price		847.4
Upfront payment		767.8
Contingent consideration (milestones)		79.6
Payments in connection with pre-existing relationships		(567.3)
Total consideration		280.1

The total consideration and the fair values determined in accordance with

IFRS 3 of the identified net assets acquired of CureVac as of the acquisition date are as follows:



		Fair value recognized on acquisition
(in millions €)		CureVac

Assets
Intangible assets		240.3
Property, plant and equipment and right-of-use assets		116.3
Cash and cash equivalents		264.5
Other assets non-current and current		26.3
Total assets		647.4

Liabilities
Non-current liabilities		43.5
Current liabilities		213.6
Total liabilities		257.1

Total identifiable net assets at fair value		390.3

Goodwill from the acquisition		10.6
Total consideration		400.9

Consideration
Fair value of shares transferred		1,001.1
thereof fair value of shares from first and second offer period transferred		868.4
thereof fair value of shares for the back-end measures		132.7
Cash paid (fractional shares)		0.1
Effects in connection with pre-existing relationships		(600.3)
Total consideration		400.9